U.S. Airlines Stock News

Event overview and recent share performance Sterling Infrastructure (STRL) is back on investors’ radar after a sharp single day move, with the stock down about 4% over the latest session and 9.6% over the past week. Those short term swings contrast with gains of 16% over the past month, 28.5% in the past 3 months and a 30.2% year to date return, prompting fresh attention on what is driving sentiment. See our latest analysis for Sterling Infrastructure. Short term, the recent 1 day share price...

If you are wondering whether Sea's current share price offers value for your money, this article will walk through what the market might be pricing in and how that lines up with the underlying business. Sea's share price closed at US$87.82, with returns of an 18% decline over 7 days, a 24.6% decline over 30 days, a 33.2% decline year to date and a 33.6% decline over the past year, while the 3 year return sits at 9.7% and the 5 year return at a 61.6% decline. These moves have put Sea back on...

Fresh coverage has pushed Toast (TOST) back into focus, spotlighting its role as a core integration layer across 156,000 restaurant locations that process US$51.5b in payments, alongside new enterprise wins and international expansion. See our latest analysis for Toast. Fresh coverage around Toast's role as a core restaurant platform arrives after a mixed stretch for the stock, with a 1-day share price return of 5.59% and 7-day share price return of 13.84%, set against a 30-day share price...

uniQure N.V. has reported full-year 2025 results, with revenue of US$16.1 million versus US$27.12 million a year earlier and a net loss of US$198.97 million versus US$239.56 million, alongside rising investor scrutiny over its Huntington’s disease program. Multiple securities class action lawsuits now allege that uniQure misrepresented aspects of its AMT-130 Huntington’s trial design and regulatory timelines, intensifying focus on how core pipeline disclosures align with future regulatory...

Why Immunome’s latest update caught investor attention Immunome (IMNM) has been in focus after management highlighted progress across its oncology pipeline, including top-line Phase 3 results for Varegacestat in desmoid tumors, alongside full year 2025 earnings that showed a smaller net loss. See our latest analysis for Immunome. Despite the clinical and earnings updates, Immunome’s share price has eased recently, with a 30 day share price return of a 12.51% decline, even though the 90 day...

General Mills (GIS) has come under closer investor scrutiny after cutting its full-year EPS guidance to a 16% to 20% decline, along with sharp drops in net income and operating income tied to affordability pressures. See our latest analysis for General Mills. Those guidance cuts and profit pressures have come alongside softer recent trading, with a 1-day share price return of 1.29% decline, 30-day share price return of 3.72% decline, and a 1-year total shareholder return of 23.51% loss,...

BigBear.ai Holdings (BBAI) just posted its FY 2025 numbers, closing out the year with Q4 revenue of US$27.3 million and a basic EPS loss of US$0.01, alongside a trailing twelve month basic EPS loss of US$0.82 on revenue of US$127.7 million. Over recent quarters the company has seen quarterly revenue move from US$43.8 million in Q4 2024 to US$27.3 million in Q4 2025. Basic EPS has ranged from a loss of US$0.58 in Q4 2024 to a small profit of US$0.01 in Q3 2025, before slipping back into a...

Nuvation Bio FY 2025 Earnings Snapshot Nuvation Bio (NUVB) has wrapped up FY 2025 with fourth quarter revenue of about US$41.9 million and a basic EPS loss of US$0.11, as the market weighs solid top line figures against continued bottom line pressure. The company has seen revenue move from US$5.7 million in Q4 2024 to US$41.9 million in Q4 2025, while quarterly basic EPS has ranged from a loss of US$0.15 in Q4 2024 to a loss of US$0.11 in Q4 2025 and a trailing twelve month basic EPS loss of...

Halozyme Therapeutics (NasdaqGS:HALO) has agreed to acquire Hypercon and several biotech startups, expanding its drug delivery and platform capabilities. The Hypercon deal extends Halozyme’s intellectual property coverage into the 2040s, supporting long term use of its core technologies. The company recently reported new ENHANZE-enabled collaborations and fresh global regulatory approvals for subcutaneous formulations using its platform. Halozyme Therapeutics, trading at $69.4, has recorded...

Without a clear headline event, DigitalBridge Group (DBRG) still attracts attention as a digital infrastructure focused asset manager, with recent returns and fundamentals giving investors several angles to reassess the stock’s current pricing. See our latest analysis for DigitalBridge Group. At a share price of US$15.46, DigitalBridge Group’s recent 90 day share price return of 56.8% contrasts with a 42.35% 1 year total shareholder return and a 5 year total shareholder return of 41.5%. This...

If you are wondering whether Progressive's share price still reflects its true worth after a strong multi year run, starting with the current valuation story can help you frame your next move. The stock last closed at US$213.35, with returns of 3.5% over the past week, 2.6% over the past month, 0.6% year to date, a 19.8% decline over the past year, and 61.2% and 164.7% over the past three and five years respectively. Recent headlines around Progressive have focused on the company as a major...

Ubiquiti (UI) recently caught investors’ attention after being upgraded to a Zacks Rank #1. This move is tied to higher earnings estimates and renewed focus on how its current valuation stacks up. See our latest analysis for Ubiquiti. Ubiquiti’s share price has moved to US$762.35, with a 38.25% 1 month share price return and 35.24% 3 month share price return, while its 1 year total shareholder return of 137.14% points to strong longer term momentum around the recent earnings upgrade. If...

CME Group has recently expanded its regulated cryptocurrency futures suite to include Cardano, Chainlink, and Stellar, and announced plans for 24/7 crypto futures and options trading access starting May 29, pending regulatory approval. This push deeper into digital asset derivatives signals CME’s intent to become a core venue for institutional and retail crypto risk management under regulatory oversight. We’ll now examine how CME’s move to 24/7 crypto derivatives trading could reshape its...

Astera Labs (ALAB) is back in focus after its move into advanced optical interconnects, marked by the aiXscale Photonics acquisition, the establishment of an Israel Design Center, and a growing role in the UALink consortium with major hyperscalers. See our latest analysis for Astera Labs. Despite the recent flurry of AI infrastructure announcements, Astera Labs’ share price has pulled back. The 1-day share price return shows an 8.92% decline and the 30-day share price return shows a 27.10%...

AST SpaceMobile (NasdaqGS:ASTS) has signed a commercial agreement with TELUS to deliver space based cellular broadband to remote parts of Canada. The deal includes TELUS investing in AST SpaceMobile's satellite infrastructure and taking an equity stake in the company. AST SpaceMobile reports that it has moved from an R&D focus to commercial operations, with new satellite deployments and contracts across commercial and defense customers. For investors watching NasdaqGS:ASTS, this update...

American International Group (AIG) recently reported a 51% year over year increase in Q4 adjusted after tax income, along with plans for at least US$1 billion in 2026 share repurchases and low to mid teens net premiums written growth. See our latest analysis for American International Group. AIG’s recent Q4 earnings jump and capital return plans come after a mixed year for the stock, with a 5.58% 1 month share price return and a 1.13% 1 year total shareholder return. The shorter term share...

In late February 2026, ImmunityBio reported strong interim Phase 2 data for ANKTIVA plus BCG in BCG-naïve non-muscle invasive bladder cancer and advanced international commercialization through new approvals and partnerships across Europe and the Middle East. This combination of earlier-than-planned trial enrollment completion, statistically significant response durability, and rapid global rollout meaningfully strengthens ANKTIVA’s role at the center of ImmunityBio’s business. We will now...

Edgewise Therapeutics reported a fourth-quarter 2025 net loss of US$50.22 million and a full-year 2025 net loss of US$167.8 million, alongside widening losses per share from continuing operations compared with the prior year. The company also highlighted upcoming presentations of new sevasemten data in Becker muscular dystrophy at the Muscular Dystrophy Association Clinical and Scientific Conference, underlining how clinical progress remains central to its story despite continued...

In February 2026, Dropbox, Inc. reported fourth-quarter 2025 sales of US$636.2 million and full-year sales of US$2.52 billion, alongside higher quarterly and annual net income, while also completing two share repurchase programs totaling US$1.46 billion and filing a US$300.47 million shelf registration for 12,150,187 Class A shares tied to an ESOP offering. This combination of improving profitability despite slightly lower sales, sizeable buybacks, and a new employee share-related shelf...

NCR Atleos (NATL) has drawn fresh attention after recent trading, with the stock closing at $48.06 and showing strong short term and past 3 months moves that stand out against its longer history. See our latest analysis for NCR Atleos. That recent burst of momentum, with a 7 day share price return of 18.7% and 90 day share price return of 28.4% at a last close of US$48.06, sits against a much stronger 1 year total shareholder return of 87.1%. This hints that sentiment around NCR Atleos has...

NextEra Energy, Inc. recently completed a US$2.00 billion public offering of 40,000,000 equity units at US$50.00 each, with a US$0.75 per unit discount, combining future stock purchase contracts with debentures issued by NextEra Energy Capital Holdings and guaranteed by the parent company. The company plans to channel the proceeds into funding energy and power projects, general corporate purposes, and repayment of outstanding commercial paper, underscoring how it is using hybrid equity–debt...

Prosperity Bancshares (NYSE:PB) is reportedly attracting acquisition interest tied to its Texas focused franchise. Recent changes to executive change in control agreements suggest management could be more aligned with a potential sale. Takeover speculation is emerging as regional bank M&A activity remains active across the sector. Prosperity Bancshares, trading at $70.04, sits at the center of fresh takeover chatter as larger banks and peers look for scale in Texas. The company is drawing...

Why Norwegian Cruise Line Holdings (NCLH) is on investors’ radar Norwegian Cruise Line Holdings (NCLH) has drawn attention after recent share price swings, with a 1-day return near a 4% decline and a past week move around an 11% decline shaping sentiment. Over the past month the stock shows roughly a 3% decline, while the past 3 months reflect about a 13% total return, giving investors a mixed short-term picture to weigh against longer-term performance and fundamentals. See our latest...

C.H. Robinson Worldwide (CHRW) is back in focus after mixed fourth quarter 2025 results, with earnings above expectations, revenue weaker, and management highlighting cost cuts, capital spending plans, and continued cash returns to shareholders. See our latest analysis for C.H. Robinson Worldwide. The recent fourth quarter update and upcoming conference appearance come after a 21.17% 90 day share price return and a 100.88% 1 year total shareholder return, suggesting momentum has picked up...